Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Zealand Pharma to attend Jefferies and Goldman Sachs Global Healthcare Conferences Press release – No. 12 / 2019 Zealand Pharma to attend Jefferies and Goldman Sachs Global Healthcare Conferences Copenhagen, May 27, 2019 – Zealand Pharma Chief Executive Officer Emmanuel Dulac, Chief Medical and Development Officer Adam Steensberg, and Senior Vice President of Corporate and Business Development Marino Garcia will attend the Jefferies 2019 Global Healthcare Conference on June 6, 2019 in New York. Zealand Pharma is scheduled to present at 2:30 PM Eastern. On June 12, 2019, Emmanuel Dulac and Adam Steensberg will attend the Goldman Sachs 40th Annual Global Healthcare Conference in Rancho Palos Verdes, California. Zealand Pharma is scheduled to present at 1:20 PM Pacific.
2 van de 3 fase 3 trials met succes achter de rug voor dasiglucagon. Na een eventuele goedkeuring begin 2020 heeft Zealand een medicijn in huis met een marktpotentieel van een miljard dollar per jaar. Verder genoeg cash in huis, met glepaglutide nog een fase 3 medicijn in de pijplijn, orphan drug approbal voor dasiglucon en glepaglutide, meerdere samenwerkingsverbanden enz. enz. Ik voorzie een mooie toekomst voor dit bedrijf
Beta Bionics and Zealand Pharma announce superior glycemic control in Phase 2 home-use clinical trial testing the iLet™ bionic pancreas using dasiglucagion First home-use trial of the iLet Bionic Pancreas System using pre-filled cartridges of dasiglucagon compatible with iLet has been successfully completed The preliminary study results reveal superior blood glucose control during the study period that used the bihormonal configuration of the iLet with dasiglucagon compared to the period that used the insulin-only configuration iLet therapy was initialized with body weight only, with no device training periods, and with no physician intervention to optimize therapy Boston, MA and Copenhagen, Denmark – June 6, 2019 – Beta Bionics, Inc. and Zealand Pharma A/S (NASDAQ: ZEAL, company announcement No. 19/2019) announced today that a home-use study of dasiglucagon in the iLet™ Bionic Pancreas System has been successfully completed. The iLet, developed by Beta Bionics, is the world’s first autonomous bionic pancreas device — a bihormonal system leveraging lifelong machine learning and artificial intelligence to deliver insulin and glucagon analogs for the autonomous treatment of type 1 diabetes (T1D). In addition to dosing insulin, the iLet doses dasiglucagon — a glucagon analog with a unique stability profile in a ready-to-use aqueous solution. Dasiglucagon is in development by Zealand Pharma. This home-use clinical trial was conducted by Dr. Steven Russell and his clinical research team at the Massachusetts General Hospital (MGH) and was designed as a randomized, two-period, cross-over trial to assess whether the iLet operated as intended. The trial compared operational performance of the iLet in the insulin-only configuration for one week versus the bihormonal configuration for one week in 10 adult participants with T1D. Trial participants started therapy by entering only their body weight into the device; there was no device training period and no physician intervention to optimize therapy. The iLet is designed to autonomously and continuously adapt to each patient’s changing insulin needs. This adaptation is typically most pronounced in the first 24 hours after the initiation of therapy. The iLet operated as expected, meeting the primary aim of the study. Preliminary data analysis demonstrated that the bihormonal iLet using dasiglucagon provided superior glycemic control over the insulin-only iLet. During the bihormonal period, participants achieved a mean glucose level, as measured by continuous glucose monitoring (CGM), of 139 mg/dL on days 2–7 of use, versus 149 mg/dL during the insulin-only period (p <0.01). During the bihormonal period, participants spent 79% of the time with their CGM glucose level in range (70–180 mg/dL) on days 2–7 of use, versus 71% during the insulin-only period (p<0.01). During the bihormonal period, 90% of participants had a mean CGM glucose level of < 154 mg/dL, a level that corresponds to an HbA1c level of 7%, the therapeutic goal for adults recommended by the American Diabetes Association. In contrast, 50% of participants had a mean CGM glucose level < 154 mg/dL during the insulin-only period. Hypoglycemia was observed to be low throughout the study. The mean percentage of time CGM glucose was < 54 mg/dL was 0.3% during the bihormonal period versus 0.6% during the insulin-only period. The mean percentage of time CGM glucose was < 70 mg/dL was 2.4% during the bihormonal period versus 3.6% during the insulin-only period. “We are extremely pleased to have now tested the performance of our bihormonal iLet Bionic Pancreas System with dasiglucagaon — the first-ever, liquid-stable glucagon analog — in a convenient ready-to-use, pre-filled cartridge designed to fit our system,” said Ed Damiano, Co-founder and President & CEO of Beta Bionics. “Preliminary results from this trial have helped reaffirm the final implementation of our dosing algorithms in the bihormonal configuration of the iLet. I am ecstatic about this historic achievement for Beta Bionics, Zealand Pharma, and our clinical collaborators at MGH, and I am looking forward with eager anticipation to the day when people with T1D can enjoy the real-life benefits of combining ready-to-use dasiglucagon with the iLet.” Beta Bionics and Zealand Pharma have partnered to carry out several co-development activities with the primary goal of obtaining regulatory approval to use dasiglucagon in the bihormonal configuration of the iLet. “The bihormonal iLet Bionic Pancreas System demonstrated tight glycemic control in a home-use setting with dasiglucagon,” commented Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma. “We look forward to proceeding with the Phase 3 trial and continuing to demonstrate the transformational opportunity that the iLet with dasiglucagon could offer for improved and fully automated diabetes management.” Beta Bionics and Zealand Pharma are planning for a Phase 3 pivotal trial testing the bihormonal configuration of the iLet with dasiglucagon in 2020. That trial is intended to support regulatory submission to the U.S. FDA of a pre-market approval (PMA) application and a new drug application (NDA) for the bihormonal configuration of the iLet with dasiglucagon in people with T1D.
Zealand Pharma presents dasiglucagon pivotal Phase 3 trial data at the 79th Scientific Sessions of the American Diabetes Association (ADA) Press release – No. 14 / 2019 Zealand Pharma presents dasiglucagon pivotal Phase 3 trial data at the 79th Scientific Sessions of the American Diabetes Association (ADA) The pivotal Phase 3 trial demonstrates that a single dose of dasiglucagon rapidly increases blood glucose levels in type 1 diabetes patients with low plasma glucose The median time to plasma glucose recovery was 10 min following dasiglucagon injection, with 99% of patients having recovered within 15 minutes
Technische analyse. Het aandeel doorbrak op 3 juni de steun van het (opgaande) trendkanaal. Op dit moment (koers circa 143 dkk) komt het aandeel weer in dat trendkanaal. De Stoch RSI geeft aan dat er nog ruimte voor stijging is ("oversold"). Zie plaatje: invst.ly/b035m Mits er geen negatieve berichten verschijnen, zou ik zeggen dat de kans groot is dat de stijging nog even doorzet.
Voor de liefhebber... In bijgaand plaatje kun je het stijgende trendkanaal zien van het aandeel Zealand Pharma sinds begin 2019. De verschillende rode lijnen geven de steunen en weerstanden van de koers aan. Plaatje: invst.ly/b3946
Prachtige stijging vanaf 2019 te zien. Ik verwacht zelf dat we nog wel even doorstijgen. Er zit nog zoveel aan te komen de komende tijd en Zealand heeft eigenlijk nog nooit teleurgesteld. Ik verbaas me er eigenlijk over hoe onbekend dit aandeel is
Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome Press release – No. 16 / 2019 Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome Short bowel syndrome (SBS) is a complex chronic and severe condition associated with reduced or complete loss of intestinal function and significant unmet medical need ZP7570 is a long-acting peptide therapeutic with dual activity on the GLP-1 and GLP-2 receptors Pre-clinical and clinical data suggest that the combined GLP-1 and GLP-2 activity may work synergistically to further improve intestinal function in patients with SBS Copenhagen, June 26, 2019 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces the dosing of the first subject in a Phase 1 clinical trial to evaluate the safety and tolerability of ZP7570 as a potential first-in-class next generation treatment of short bowel syndrome (SBS). The study is a randomized, double-blind, placebo-controlled, single ascending dose trial in 64 healthy subjects, randomized to ZP7570 or placebo within eight cohorts. ZP7570, a long-acting, dual GLP-1/GLP-2 peptide therapeutic, is designed to further improve management of SBS and may represent a next level of innovation for helping SBS patients to further realize full potential for intestinal rehabilitation. GLP-2 primarily increases the absorptive capacity of the intestine, whereas GLP-1 is believed to act by reducing gastrointestinal motility, thereby allowing more time for the fluids and nutrition to be absorbed. The properties of ZP7570 may also allow for therapeutic opportunities in other gastrointestinal diseases. “We are committed to changing the lives of people with short bowel syndrome and see good progress in our Phase 3 clinical trial with glepaglutide, a potential best-in-class long-acting GLP-2 analog for treatment of SBS,” commented Adam Steensberg, Executive Vice President and Chief Medical and Development Officer at Zealand Pharma. “Initiation of this Phase 1 clinical trial with ZP7570, a dual- GLP-1/GLP-2 acting peptide, marks yet another important milestone in our efforts to bring innovative therapeutics to patients living with SBS.”
De koers van 141DKK is in het verleden al meerdere malen een weerstand gebleken. En ook nu weer. Zie plaatje: invst.ly/b4j5r De volumes zijn laag en dat helpt ook niet om deze weerstand te doorbreken. Echter, vanaf aanstaande maandag zitten we in Q3 en in dat kwartaal worden de fase 3-resulaten verwacht van het medicijn tegen severe Hypoglycemia. En die lijken veelbelovend!
Koers trekt zich nu weinig aan van die weerstand... ;o)
Gisteren heeft de koers een krachtig signaal afgegeven. De koers was als het ware in een hoekje gedreven (blauwe driehoek in plaatje) en was zo op een punt gekomen dat óf de weerstand doorbroken moest worden óf de steun van de opgaande trendlijn. Dat laatste gebeurde én op overtuigende wijze. Zie plaatje ter verduidelijking: invst.ly/b4uh4
Correctie.... Gisteren heeft de koers een krachtig signaal afgegeven. De koers was als het ware in een hoekje gedreven (blauwe driehoek in plaatje) en was zo op een punt gekomen dat óf de weerstand doorbroken moest worden óf de steun van de opgaande trendlijn. Dat EERSTE gebeurde én op overtuigende wijze. Zie plaatje ter verduidelijking: invst.ly/b4uh4
Mr. Buffett schreef op 28 juni 2019 07:43 :
De koers van 141DKK is in het verleden al meerdere malen een weerstand gebleken. En ook nu weer. Zie plaatje:
invst.ly/b4j5r De volumes zijn laag en dat helpt ook niet om deze weerstand te doorbreken. Echter, vanaf aanstaande maandag zitten we in Q3 en in dat kwartaal worden de fase 3-resulaten verwacht van het medicijn tegen severe Hypoglycemia. En die lijken veelbelovend!
Klopt, ik heb er alle vertrouwen in. In het PB van 14 mei staat het volgende: The final Phase 3 trial that will complete our NDA application is in pediatric diabetes patients and is still ongoing. Recruitment for this study involving children has proved challenging and results are now expected in September 2019. Accounting for this delay in pediatric patient recruitment, submission of the new drug application (NDA) to the U.S. FDA is now expected early 2020. Gaat dus waarschijnlijk september worden.
Erg hoog volume in de US, met een uitschieter naar €23...
Een ander Deens biotech-bedrijf dat technisch gezien interessant lijkt, is Bavarian Nordic. In 2017 verloor het aandeel de helft van haar waarde vanwege stopzetten van een phase 3-onderzoek naar prostaatkanker en is de afgelopen twee jaar in een neergaande spiraal terecht gekomen. Eind mei heeft het aandeel dat neergaande spiraal echter doorbroken en lijkt weer de weg naar boven te zoeken. Zie plaatje: invst.ly/b5v9q Het bedrijf heeft daarnaast een brede pijplijn: www.bavarian-nordic.com/pipeline/pipe...
Interessant. Zie dat ze zich met name richten op infectieziekten en immunotherapieen tegen kanker. Lijkt me zeker de moeite waard. Ik zet hem op mijn 'te volgen lijstje'. Bedankt
ZEAL in Uptrend: 50-day Moving Average broke above 200-day Moving Average on March 11, 2019 A buy signal is indicated by this change in price, due to the trend repositioning higher. In 1 of 1 cases where ZEAL's 50-day Moving Average crossed above its 200-day Moving Average, its price rose further within the subsequent month. The odds of a continued Uptrend are 90%.
Van Herk Investments heeft zich belang in Galapagos uitgebreid. Dat meldt het biotechnologiebedrijf in een transparantieverklaring Van Herk heeft er kijk op. Hij heeft ook een aanzienlijke positie in Zealand.
Uit een eerdere conference call: Glucagon Hypoglycaemia Rescue Market Has Substantial Value Potential On page five, we see the current and expected volume and value for the glucagon hypoglycaemia rescue market. We believe this is an underpenetrated market due to the shortcomings of the current product as well as lack of promotion for many decades. With new and better products that are easier to administer, we believe the rescue products will grow significantly and reach $1 billion in the US alone by 2030. Now, I’ll turn it over to Adam to discuss the pivotal Phase 3 trial and results in detail.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
873,52
+0,81%
EUR/USD
1,0701
+0,46%
FTSE 100
8.029,75
+0,07%
Germany40^
18.076,60
+1,21%
Gold spot
2.323,50
-0,16%
NY-Nasdaq Composite
15.451,31
+1,11%
Stijgers
Dalers